Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 Authors: Daniel Rusu, Aidan Lindgren, Natalie M Kistler, Niels Mohty, Thomas W Mason, Marc A Abdou, Jeffrey C Wang, Raymond J Hah, Ram K Alluri Published: 2026 ABSTRACT AbstractStudy DesignRetrospective Cohort.ObjectivesTo evaluate trends in bone morphogenetic protein (BMP) utilization across spinal fusion procedures.MethodsPatients undergoing anterior cervical discectomy and fusion (ACDF), posterior cervical decompression and fusion (PCDF), anterior lumbar interbody fusion (ALIF), or posterior/transforaminal lumbar interbody fusion (PLIF/TLIF) between January 1, 2010 and April 30, 2023 were identified in the PearlDiver Mariner Database. BMP utilization was identified using ICD-9/10 codes and assessed annually as a percentage of total cases, with 2023 omitted due to incomplete data. Subgroup analysis stratified annual trends by number of levels fused. Temporal trends in patient demographics were compared between early (2010-2016) and late (2017-2023) cohorts using Welch’s t-test and Pearson chi-squared test of independence.ResultsA total of 596,453 ACDF, 104,287 PCDF, 159,575 ALIF, and 622,252 PLIF/TLIF cases were identified, respectively. Across all procedures, BMP utilization declined to a nadir in 2017, followed by marked increase. From 2017 to 2022, BMP utilization increased by 667% in ACDF, 1138% in PCDF, 441% in ALIF, and 900% in PLIF/TLIF. BMP use was higher in multi-level PCDF and PLIF/TLIF compared to single-level, whereas ALIF demonstrated slightly higher utilization in single-level cases. In the later cohort, patients receiving BMP were older, had greater comorbidity burden, and longer hospital stays across all procedures (p<0.001).ConclusionsBMP utilization in spine surgery declined steadily until 2017, followed by marked increase through 2022, particularly in multi-level posterior cervical and lumbar fusions and among high-risk patients. This likely reflects evolving evidence supporting optimized dosing and improved safety profiles.Keywords: bone morphogenetic protein, BMP, spinal fusion, utilization trends, back pain Introduction The increasing prevalence of spine surgery has driven the adoption and refinement of biologic adjuncts aimed at improving fusion outcomes. Bone Morphogenetic Proteins (BMPs), a well-established group of growth factors, have been proven to increase osteogenesis following spinal fusion surgery.1-3 BMP rapidly gained popularity as an alternative to iliac crest bone grafts for lumbar fusions due to its superior osteogenic potential, fusion rates, and low level of complications compared to its counterpart.2,4 Due to this favorable profile, recombinant human BMP (rhBMP-2, “INFUSE”) was approved by the Food and Drug Administration (FDA) for use in single-level anterior lumbar interbody fusion (ALIF) procedures in 2002. 2 Despite only being approved for single-level ALIF, BMP was increasingly utilized for “off-label” indications, and has seen utility in as many as 30% of posterior lumbar interbody fusion cases, 30% of transforaminal interbody fusion cases, 20.4% of posterolateral spine fusion cases, and 13.6% of cervical fusion cases in 2006. 1 The growth in usage was similarly followed by growth in reported complications, including heterotopic ossification, prevertebral swelling, osteolysis, seroma or hematoma, radiculitis, infection, increased neurological deficits (myelopathy, radiculopathy), and increased cancer rates.1,5,6 Consequently, the FDA issued an advisory warning for BMP usage in 2008. Later in 2011, Carragee et al compared results and conclusions from original industry-sponsored publications on BMP’s safety and efficacy with available FDA data summaries, finding the risk of adverse events to be 10-50 times higher than original estimates in industry-supported publications. 7 Although BMP utilization largely decreased as a result, it is still utilized by many providers.5,8 While recent research has demonstrated BMP’s favorable safety profile and efficacy, there are few publications depicting current practice patterns of BMP utilization in spinal fusion surgeries.9,10 The current study aimed to evaluate current trends in BMP (rhBMP-2 and rhBMP-7) utilization across 4 major spinal procedural categories: anterior cervical discectomy and fusion (ACDF), posterior cervical decompression and fusion (PCDF), anterior lumbar interbody fusion (ALIF), and posterior or transforaminal lumbar interbody fusion (PLIF/TLIF). We hypothesize that there has been a recent resurgence in BMP use in spinal fusion surgeries. Methods Data Source The patient population was queried from the PearlDiver Mariner Database (PearlDiver Technologies, Colorado Springs, CO). All patients who underwent ACDF, PCDF, ALIF, or PLIF/TLIF were identified from the database. PearlDiver is a national insurance claims database that contains approximately 170 million de-identified patients with records from January 1, 2010 to April 30, 2023. 11 Due to the use of anonymized data and the retrospective nature of this study, approval from an institutional review board was waived. Cohort Identification All patients who underwent ACDF, PCDF, ALIF, or PLIF/TLIF between 2010 and 2023 were identified using CPT codes. Patients who had surgical indications for neoplasm, infection, or trauma were excluded. Patients were then subdivided into those who had spinal fusion with BMP utilization using ICD-9 and ICD-10 procedure codes (Supplementary Table 1). To compare trends in patient characteristics for BMP utilization over time, patients who had spinal fusion with BMP were dichotomized by time period: 2010-2016 and 2017-2023. Primary and Secondary Endpoints The primary outcome of this study was to analyze utilization trends of BMP in spinal fusion across 4 different spinal procedural categories between 2010 and 2022. Utilization of BMP was assessed as a percentage of the total number of cases per year performed for each spinal fusion procedure. Each cohort was then sub-divided based on the number of levels fused: 1 level, 2 levels, or 3+ levels–using CPT add-on codes (Supplementary Table 1). Percentage of BMP utilization was compared across the number of levels fused. Lastly, temporal trends in patient demographics and descriptive characteristics–Elixhauser Comorbidity Index (ECI), length of stay (LOS), insurance plan, clinical setting, physician specialty, education status, mean family income, and region–were compared between the earlier (2010-2016) and latter (2017-2023) cohorts. As a sensitivity analysis, risk factors for pseudarthrosis including age, ECI, and multi-level fusion were compared between spinal fusions augmented with BMP to those without BMP (Supplementary Table 2). Statistical Analysis Pearson chi-squared tests of independence were performed to compare the proportion of patients between the 2 time period cohorts. Data from 2023 was omitted in trends analysis to avoid interpreting results from an incomplete year. To compare age and ECI between time periods, Welch’s t-tests were performed. All statistical analyses were conducted using R Studio (Version 4.4.2) within the PearlDiver Mariner Database program. Statistical significance was defined as a p-value <0.05. Results Between January 1, 2010 and April 30, 2023, 596,453 ACDF patients, 104,287 PCDF patients, 159,575 ALIF patients, and 622,252 PLIF/TLIF patients were identified. BMP Utilization per Year The number of ACDFs performed per year remained approximately stable throughout the study period with a range of 41,819 to 48,999 cases per year. The percentage of ACDF cases that utilized BMP began at a maximum of 1.83% in 2010 followed by subsequent decrease to a nadir of 0.03% in 2017. Following 2017, BMP utilization in ACDF continued to slowly increase to 0.23% in 2022, an increase of 667% (absolute increase: 0.2%) since 2017 (Figure 1). Number and Percent of ACDF cases using BMP per Year From 2010 to 2022, PCDF cases increased steadily from 5,417 in 2010 to 9,680 in 2022. In 2010, 4.56% of PCDF cases BMP followed by a decrease in utilization to 0.21% of PCDF cases in 2017. BMP utilization then increased to 2.6% in 2022, an increase of 1138% (absolute increase: 2.39%) since 2017 (Figure 2). Number and Percent of PCDF cases using BMP per Year ALIFs performed per year increased marginally from 10,277 in 2010 to 14,558 in 2022. The percent of ALIF cases using BMP decreased initially from 13.06% in 2010 to 1.60% in 2017, followed by a subsequent increase to 8.66% in 2022, an increase of 441% (absolute increase: 7.06%) since 2017 (Figure 3). Number and Percent of ALIF cases using BMP per Year Lastly, the number of PLIF/TLIFs per year remained stable over time, with a range of 42,554 to 53,141 cases. BMP utilization in PLIF/TLIFs started at 9.69% in 2010 with initial decline to 0.47% in 2017. This was followed by an increase to 4.70% of PLIF/TLIF cases utilizing BMP in 2022, an increase of 900% (absolute increase: 4.23%) since 2017 (Figure 4). Number and Percent of PLIF/TLIF cases using BMP per Year BMP Utilization by Number of Levels In ACDF cases, patients who underwent fusion at 2 or more levels had higher utilization rates of BMP between 2011 to 2016. Following the inflection point in 2016-2017, BMP utilization across all numbers of levels was similar. In 2022, BMP utilization was marginally greater in multi-level fusion by ∼0.1-2% (Figure 5). Percent of ACDF cases using BMP Per Level by Number of Levels For patients who underwent PCDF, utilization of BMP was greater in fusion of 2 or more levels beginning in 2019, with BMP utilization in multi-level fusion being greater by ∼0.5% when compared to single-level fusion (Figure 6). Percent of PCDF cases using BMP Per Level by Number of Levels In ALIFs, BMP utilization was marginally greater in single-level fusion than 2 or more level fusion across all years (Figure 7). Percent of ALIF cases using BMP Per Level by Number of Levels Lastly, BMP utilization in PLIF/TLIFs was consistently greater in multi-level fusion across all years, with the greatest discrepancies between 2020-2022 at nearly twice as much BMP utilization for fusions at additional levels (Figure 8). Percent of PLIF/TLIF cases using BMP Per Level by Number of Levels BMP Patient Characteristics Over Time Patient characteristics between the two temporal cohorts (2010-2016 and 2017-2023) were compared. In the later cohort, patients who underwent ACDF with BMP were older (58.7 vs 54.5 years), had greater comorbidity burden (ECI 6.94 vs 3.28), and a longer hospital stay (4.12 vs 1.93 days) when compared to the earlier cohort (p<0.001). From 2017-2023, more patients who received BMP were classified as having a mean family income >$75,000 (44.05% vs 17.46%), high education status (13.22% vs 3.52%), and Medicaid (9.69% vs 3.73%), but fewer patients had commercial insurance (70.04% vs 78.09%) (p<0.001). In PCDF cases utilizing BMP, patients in the later cohort were older (62.2 vs 59.3 years), had greater comorbidity burden (ECI 8.05 vs 4.71), and a longer hospital stay (5.89 vs 4.29 days) (p<0.001). From 2017-2023, more patients receiving BMP for PCDF were classified as having a mean family income >$75,000 (40.68% vs 18.62%, p<0.001), high education status (15.01% vs 5.10%, p<0.001), and had Medicaid insurance (9.01% vs 5.43%, p=0.001). Over time, fewer neurosurgeons (40.17% vs 59.68%, p<0.001) and more orthopaedic surgeons (30.64% vs 24.37%, p=0.001) utilized BMP for PCDF. Patients who underwent ALIFs using BMP were older (59.64 vs 52.79 years), had higher comorbidity burden (ECI 6.14 vs 3.38), and longer length of stay (3.66 vs 3.25 days) in the later cohort (p<0.001). From 2017 to 2023, more patients were classified as having a mean family income >$75,000 (43.48% vs 21.02%), high education status (15.16% vs 6.91%), and either Medicaid (6.52% vs 5.61%, p=0.048) or Medicare (24.57% vs 17.52%) (p<0.001 unless otherwise specified). Lastly, patients who had PLIF/TLIFs with BMP were older (63.06 vs 58.02 years), had higher comorbidity burden (ECI 6.81 vs 3.77), and longer hospital stay (3.85 vs 3.61 days) in the later cohort (p<0.001). In the later cohort, more patients were classified as having a mean family income >$75,000 (40.69% vs 18.29%), high education status (14.81% vs 5.93%), and Medicare (24.25% vs 21.43%), but fewer patients had commercial insurance (71.34% vs 73.02%, p=0.003) (p<0.001 unless otherwise specified). Over time fewer neurosurgeons (48.15% vs 51.97%) but more orthopaedic surgeons (45.99% vs 40.57%) utilized BMP for PLIF/TLIFs (p<0.001) (Tables 1 and 2). Table 1.Comparison of Patient Demographics and Descriptive Characteristics for Each Cervical Spine Surgery Utilizing BMP Between the Two Time Period CohortsCervicalACDF with BMPPCDF with BMPVariable2010-2016 (N=3322)2017-2023 (N=454)p-value2010-2016 (N=1235)2017-2023 (N=966)p-value mean sd mean sd mean sd mean sd Age54.78410.83358.74712.461 <0.001 59.27511.63362.20512.745 <0.001 ECI3.2842.8296.9414.201 <0.001 4.7113.2428.0534.378 <0.001 LOS1.9312.084.1242.925 <0.001 4.2873.7145.8885.782 <0.001 ​ N % N % p-value N % N % p-valueFemale177753.4925255.510.44962250.3646047.620.217Male154546.5120244.490.44961349.6450652.380.217ECI ≥4126137.9634776.43 <0.001 73959.8482184.99 <0.001 ECI ≤3206162.0410723.57 <0.001 49640.1614515.01 <0.001 Income >$75,00058017.4620044.05 <0.001 23018.6239340.68 <0.001 Income<$75,000174952.6510122.25 <0.001 69256.0318919.57 <0.001 Neurosurgeon205861.9527761.010.73873759.6838840.17 <0.001 Orthopaedic surgeon98529.6512727.970.49630124.3729630.64 0.001 Region Northeast58317.556414.100.07817314.0113714.180.956Midwest74222.3411625.550.14143134.9035236.440.481West40412.167716.96 0.005 12610.2013413.87 0.01 South158147.5919643.170.08650040.4933834.99 0.01 Insurance ​​​​​​​​​​Medicaid1243.73449.69 <0.001 675.43879.01 0.001 Medicare52715.868919.600.05139431.9033034.160.283Commercial259478.0931870.04 <0.001 83867.8566068.320.851High Education status1173.526013.22 <0.001 635.1014515.01 <0.001 Low Education status1634.9181.76 0.004 544.37111.14 <0.001 ACDF = Anterior Cervical Discectomy and Fusion, PCDF = Posterior Cervical Decompression and Fusion, BMP = Bone Morphogenetic Protein, ECI = Elixhauser Comorbidity Index, LOS = Length of Stay, sd = Standard Deviation. Bolded p-values signify statistical significance. Comparison of Patient Demographics and Descriptive Characteristics for Each Cervical Spine Surgery Utilizing BMP Between the Two Time Period Cohorts ACDF = Anterior Cervical Discectomy and Fusion, PCDF = Posterior Cervical Decompression and Fusion, BMP = Bone Morphogenetic Protein, ECI = Elixhauser Comorbidity Index, LOS = Length of Stay, sd = Standard Deviation. Bolded p-values signify statistical significance. Table 2.Comparison of Patient Demographics and Descriptive Characteristics for Each Lumbar Spine Surgery Utilizing BMP Between the Two Time Period CohortsLumbarALIF with BMPPLIF/TLIF with BMPVariable2010-2016 (N=6457)2017-2023 (N=4770)p-value2010-2016 (N=18,659)2017-2023 (N=9,167)p-value mean sd mean sd mean sd mean sd Age52.79412.72659.64112.626 <0.001 58.0212.40463.05511.968 <0.001 ECI3.3812.7486.1363.841 <0.001 3.7692.7766.8113.911 <0.001 LOS3.2462.1343.6563.057 <0.001 3.6132.1453.8533.05 <0.001 ​ N % N % p-value N % N % p-valueFemale385859.75267556.08 <0.001 1104159.17527957.59 0.012 Male259940.25209543.92 <0.001 761840.83388842.41 0.012 ECI ≥4256039.65343572.01 <0.001 859246.05720678.61 <0.001 ECI ≤3389760.35133527.99 <0.001 1006753.95196121.39 <0.001 Income >$75,000135721.02207443.48 <0.001 341218.29373040.69 <0.001 Income <$75,000338052.3585117.84 <0.001 1005753.90198821.69 <0.001 Neurosurgeon220034.07156932.890.198969751.97441448.15 <0.001 Orthopaedic surgeon359355.65261754.860.421757040.57421645.99 <0.001 Region Northeast101815.7768414.34 0.04 258813.87141315.41 <0.001 Midwest201231.16132927.86 <0.001 671035.96302132.96 <0.001 West82712.8181517.09 <0.001 220111.80145215.84 <0.001 South256339.69191240.080.69710838.09321935.12 <0.001 Insurance ​​​​​​​​​​Medicaid3625.613116.52 0.048 7433.983944.300.223Medicare113117.52117224.57 <0.001 399921.43222324.25 <0.001 Commercial500377.48371277.820.6881362573.02654071.34 0.003 High Education status4466.9172315.16 <0.001 11075.93135814.81 <0.001 Low Education status3144.86831.74 <0.001 7794.171461.59 <0.001 ALIF = Anterior Lumbar Interbody Fusion, PLIF = Posterior Lumbar Interbody Fusion, TLIF = Transforaminal Lumbar Interbody Fusion, BMP = Bone Morphogenetic Protein, ECI = Elixhauser Comorbidity Index, LOS = Length of Stay, sd = Standard Deviation. Bolded p-values signify statistical significance. Comparison of Patient Demographics and Descriptive Characteristics for Each Lumbar Spine Surgery Utilizing BMP Between the Two Time Period Cohorts ALIF = Anterior Lumbar Interbody Fusion, PLIF = Posterior Lumbar Interbody Fusion, TLIF = Transforaminal Lumbar Interbody Fusion, BMP = Bone Morphogenetic Protein, ECI = Elixhauser Comorbidity Index, LOS = Length of Stay, sd = Standard Deviation. Bolded p-values signify statistical significance. During both time periods, patients with spinal fusions augmented with BMP had higher comorbidity burden when compared to those without BMP augmentation across all spine surgeries. Within time periods, the relationship between BMP use and age was not consistent across procedures. All four spine procedural categories except ALIF had higher rates of multi-level fusion with BMP use (Supplementary Table 2). Discussion This study aimed to evaluate trends in BMP utilization across four major spinal procedural categories: ACDF, PCDF, ALIF, and PLIF/TLIF. From 2010 to 2022, all four spinal fusion surgeries experienced a decrease in BMP utilization reaching a nadir in 2017 with subsequent increase until 2022. In ACDF, BMP utilization was higher in multi-level fusion until 2016, after which utilization became similar across all levels. For PCDF, BMP use increased in multi-level fusion starting in 2019. In ALIF, BMP utilization was marginally higher in single-level fusions throughout the study period, whereas in PLIF/TLIF, it remained higher in multi-level fusions throughout the study period, with the largest differences observed from 2020 to 2022. Across all spinal fusion surgeries, patients from the later cohort who received BMP were older, had greater comorbidity burden, and longer hospital stays when compared to the earlier cohort. Over time, neurosurgeon utilization of BMP decreased in PCDF and PLIF/TLIF, while orthopaedic surgeons utilization of BMP increased in PCDF and PLIF/TLIF. This study identified a recent resurgence in BMP utilization across multiple spinal fusion surgeries after its nadir in 2017. Prior studies utilizing the National Inpatient Sample (NIS), Premier Perspective database, and a 20% sample of Medicare beneficiaries have reported the increase in BMP utilization in spine surgery from 2002 to 2011, with subsequent decrease in utilization until 2015.2,3,5,12-14 Our study builds upon prior work by demonstrating the continued decrease of BMP utilization until 2017, followed by a recent increase in utilization in spinal fusion surgeries. In 2002, the FDA approved the use of rhBMP-2 for single-level ALIF. Because the FDA has not extended approval beyond single-level ALIFs, spine surgeons have utilized BMP “off-label” in other fusion surgeries (ACDF, PCDF, PSF, etc). The initial observed decrease in BMP utilization is likely due to literature documenting increased adverse events following spinal fusion with BMP. In 2008, the FDA issued an advisory warning regarding complications of BMP usage in anterior cervical spine surgery, noting reports of neck and throat swelling leading to airway compression. 5 In 2011, a systematic review by Carragee et al estimated the incidence of adverse events associated with BMP in ACDFs, ALIFs, and PLIF/TLIFs was 10 to 50 times greater than previously documented FDA trial data. 7 Further studies demonstrated that BMP use was associated with increased risks of malignancy, elaborated on its complication profile, and raised concerns regarding BMP utilization in spine surgery.6-8,15 These studies have likely contributed to the observed decrease of BMP utilization in spinal fusion. The increase in BMP utilization observed after 2017 in this study is likely multifactorial. Reviews in 2016 and 2017 explored the relationship of BMP concentrations and delivery methods with complication rates across spine surgery.9,16 For example, Hofstetter et al in 2016 demonstrated that a minimum BMP concentration used in ACDF achieved improved arthrodesis with comparable complication rates as ACDF without BMP. This finding was also observed in posterior cervical fusions. Furthermore, BMP showed dose-dependent rates of fusion in ALIF and posterolateral lumbar fusion, with increasing complication rates. 9 Updated reviews and longitudinal studies on newer BMP carriers and surgeons lowering BMP doses in spinal fusion surgeries coincided with this 2017 increase.17,18 The implementation of bundled payment models, coupled with growing surgeon awareness of the cost-effectiveness and clinical utility of BMP at reduced doses, may have further influenced the observed increase in utilization patterns.19,20 Additional studies in 2020 demonstrated superior fusion rates and similar complications rates in lumbar fusion with BMP.21,22 Lastly, Dettori et al in 2019 demonstrated that use of BMP in spinal fusion did not result in increased cancer risk at 8-year follow-up. 10 The aforementioned work have provided more nuanced recommendations on BMP use, indicating that lower doses may yield superior fusion rates without increasing complication rates, thereby assuaging prior concerns. 23 This study demonstrates the discrepancy in BMP usage between anterior and posterior cervical fusions. Although prior research has demonstrated complication rates in ACDF comparable to posterior cervical procedures when utilizing low BMP concentrations, BMP usage in ACDF remains low (0.23%) when compared to PCDF (2.60%) in 2022. This may be explained in part by residual concerns regarding airway swelling and compression, which are not observed during posterior cervical fusion. Multi-level posterior fusions utilized BMP more frequently than multi-level anterior approaches, relative to their single-level counterparts. In general, multi-level spinal fusions are associated with increased rates of pseudarthrosis. 24 Furthermore, literature has demonstrated an increased risk of nonunion with posterior cervical fusion when compared to ACDF. 25 This increased risk of pseudarthrosis combined with concerns of airway complications likely contributes to the elevated BMP usage in multi-level PCDF compared to ACDF. Conversely, BMP utilization in the lumbar spine is higher in anterior approaches (8.66%) versus posterior approaches (4.70%) likely due to FDA approval for its use in single-level ALIF. Although anterior and posterior lumbar approaches have demonstrated similar rates of fusion, ALIFs have unique anterior-approach related complications. 26 Prior literature has demonstrated the association between BMP use and increased risk of these complications such as retrograde ejaculation, and retroperitoneal hematoma/seroma formation.27-29 As a result, surgeons may favor augmenting fusions with BMP in multi-level PLIF/TLIF when compared to ALIF or single-level PLIF/TLIF as the increased risk of pseudarthrosis in multi-level surgery may be perceived to outweigh the potential for BMP-related complications. Across all four spinal fusion procedures, BMP utilization was more common in patients with higher comorbidity burden and was increasingly used to augment fusion in older patients. This contrasts with early data in 2006 which demonstrated BMP use was associated with lower comorbidity burden, likely due to initial hesitation surrounding its usage. 30 Although age has not been established as a significant risk factor for pseudarthrosis in short-segment fusion, age greater than 55 years has been associated with increased risk of pseudarthrosis in 4 or more level spinal fusion for adult spinal deformity, potentially increasing likelihood of BMP use in this population.31,32 Furthermore, comorbidities such as sleep apnea, rheumatoid arthritis, tobacco smoking, long-term steroid use, and osteoporosis are well-known risk factors for pseudarthrosis following spinal fusion. 24 As a result, spine surgeons may favor BMP utilization in this high-risk population for its superior rates of arthrodesis. Limitations This study is not without limitations inherent to a retrospective claims database. These databases are reliant on accurate coding of procedures and as such this study is subject to human coding error, with respect to proper coding of levels fused and BMP usage during spinal fusion. The PearlDiver Mariner database only provides records until April 30, 2023. As a result, the percentage of cases utilizing BMP in 2023 may be assessed; however, it may not be fully representative of BMP utilization for that year and, thus, was omitted. Additionally, the PearlDiver database only includes administrative claims solely from the United States and may not entirely reflect trends for the international reader. In PearlDiver, identification of BMP augmentation is performed using ICD-9/10 procedure codes, which is not capable of specifying whether rhBMP-2 or rhBMP-7 was used. Furthermore, BMP utilization in PLIF and TLIF is aggregated due to sharing common CPT codes, including codes that use fusion techniques with and without the use of an interbody cage. This applies to the ALIF cohort as well due to the common CPT code, CPT-22558, which additionally includes oblique lateral interbody fusion, lateral lumbar interbody fusion, and other anterior or anterolateral lumbar interbody fusion approaches. The limitation of claims databases using CPT codes and aggregating different approaches increases the heterogeneity of the cohorts. Furthermore, the nadir may be partially explained by the transition from ICD-9 to ICD-10 coding in October 2015; however, the sustained decrease prior to 2015 and the continual recovery following 2017 in BMP usage is less consistent with a pure coding artifact and rather an observed shift in clinical practice. As a trends analysis, this study may only speculate as to the reasons behind the increase in BMP utilization in spine surgery without providing definite conclusions. Lastly, since BMP use is not coded specifically by vertebral level, this study is not able to account for multi-level spinal fusions that augment with BMP at fewer levels than those fused. Conclusions In spine surgery, BMP utilization decreased over time, reaching a nadir in 2017 followed by marked increases until 2022. BMP utilization has remained low in ACDF, while PLIF/TLIFs experienced the greatest increase and usage favored in multi-level posterior fusions. Patients who had spinal fusion augmented with BMP had higher comorbidity burden, likely reflecting surgeon clinical decision-making regarding risk factors for pseudarthrosis. This resurgence may reflect literature refining BMP dosing strategies, clarifying complication rates, and mitigating earlier safety concerns. Additional prospective research is warranted to expand BMP usage beyond single-level ALIF. Supplemental Material Supplemental Material - Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 Supplemental Material for Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 by Daniel Rusu, Aidan Lindgren, , Natalie M. Kistler, Niels Mohty, Thomas W. Mason, Marc A. Abdou, Jeffrey C. Wang, Raymond J. Hah, Ram K. Alluri in Global Spine Journal. Supplemental Material - Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 Supplemental Material for Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 by Daniel Rusu, Aidan Lindgren, , Natalie M. Kistler, Niels Mohty, Thomas W. Mason, Marc A. Abdou, Jeffrey C. Wang, Raymond J. Hah, Ram K. Alluri in Global Spine Journal. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DR, AL, NMK, NM, and TWM have nothing to disclose. MAA receives research support from ATEC Spine. JCW has received intellectual property royalties from Zimmer Biomet, NovApproach, SeaSpine, DePuy Synthes, and GS Medical; consulting fees from DePuy Synthes and Bioretec; and has stock options in Bone Biologics, Electrocore, PearlDiver, Surgitech, and Illuminant. RJH has received research support from ATEC and NuVasive; consulting fees from Medtronic, Globus/NuVasive, Orthofix, SI-Bone, Cerapedics, and Evolution Spine; and support for attending meetings from North American Spine Society. RKA has received consulting fees from Medtronic, Orthofix, and Globus; payment for lectures and presentations from Ecential Robotics; support for attending meetings from USC; has stock options in HIA Technologies, NeoOnc, and Globus; and has received research support from ATEC and Max BioPharma. Supplemental Material: Supplemental material for this article is available online. ORCID iDs Daniel Rusu https://orcid.org/0009-0005-5916-0484 Aidan Lindgren https://orcid.org/0009-0009-8110-9211 Natalie M. Kistler https://orcid.org/0009-0003-5369-9038 Marc A. Abdou https://orcid.org/0000-0002-3294-4001 Raymond J. Hah https://orcid.org/0000-0001-7513-3519 Ram K. Alluri https://orcid.org/0000-0001-5919-707X Ethical Considerations There are no human participants in this article and informed consent or IRB approval were not required. Data Availability Statement Data is not publicly available but can be available upon request.* References Associated Data Supplementary Materials Supplemental Material - Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 Supplemental Material for Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 by Daniel Rusu, Aidan Lindgren, , Natalie M. Kistler, Niels Mohty, Thomas W. Mason, Marc A. Abdou, Jeffrey C. Wang, Raymond J. Hah, Ram K. Alluri in Global Spine Journal. Supplemental Material - Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 Supplemental Material for Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022 by Daniel Rusu, Aidan Lindgren, , Natalie M. Kistler, Niels Mohty, Thomas W. Mason, Marc A. Abdou, Jeffrey C. Wang, Raymond J. Hah, Ram K. Alluri in Global Spine Journal. Data Availability Statement Data is not publicly available but can be available upon request.*